Figure 2

Correlations between CD45dimCD34 + KDR + cell concentration at baseline and change in LVEF (A), myocardial viability improvement (B) and in infarct size (C) in patients of the cell therapy group reassessed at three months follow-up. Black triangle: former smokers and non-smokers, white circle: active smokers at the time of AMI. No significant interactions were observed between cell number, smoking status and clinical parameters (change in LVEF: P = 0.39, in infarct size: P = 0.27, in gain of myocardial viability: P = 0.36), nor correlations between cell number and clinical parameters after adjustment for smoking status (LVEF: P = 0.68, infarct size: P = 0.99, myocardial viability improvement: P = 0.06). Myocardial viability improvement was expressed as the number of non-viable segments at baseline that were viable at three months follow-up, measured by four-hour resting SPECT. AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; SPECT, thallium-201-gated-single-photon-emission computed tomography.